Literature DB >> 31202906

Immunization against Vibrio cholerae, ETEC, and EHEC with chitosan nanoparticle containing LSC chimeric protein.

Bentol Hoda Ghaffari Marandi1, Mohammad Reza Zolfaghari1, Rouhollah Kazemi2, Mohammad Javad Motamedi2, Jafar Amani3.   

Abstract

INTRODUCTION: Severe intestinal infections caused by V. cholerae, ETEC and EHEC have contributed to the mortality rate in developing countries. Vibrio Cholera, ETEC and EHEC bacterium with the production of CT, LT and Stx2 toxins respectively lead to severe watery and bloody diarrhea. This study aimed to investigate a trimeric vaccine candidate containing recombinant chimeric protein, encapsulate the protein in chitosan nanoparticles and assess its immunogenicity.
METHODS: The LSC recombinant gene was used. It is composed of LTB (L), STXB (S) and CTXB (C) subunits respectively. The LSC recombinant protein was expressed and purified and confirmed by western blotting. The purified protein was encapsulated in chitosan nanoparticles, and its size was measured. BalB/c mice were immunized in four groups through oral and injection methods by LSC protein. The antibody titer was then evaluated by ELISA, and finally, the challenge test of the toxins from all three bacteria was done on the immunized mouse.
RESULTS: After expression and purification LSC protein size of nanoparticles containing protein was measured at 104.6 nm. Nanoparticles were able to induce systemic and mucosal immune responses by generating a useful titer of IgG and IgA. The challenge results with LT, CT and Stx toxins showed that the LSC protein might partially neutralize the effect of toxins.
CONCLUSION: LSC chimeric protein with the simultaneous three essential antigens have a protective effect against the toxins produced by ETEC, EHEC and Vibrio cholera bacteria and it can be used in vaccines to prevent Diarrhea caused by these three bacteria.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chimeric protein; Chitosan; EHEC; ETEC; Escherichia coli O157:H7; Nanoparticle

Year:  2019        PMID: 31202906     DOI: 10.1016/j.micpath.2019.103600

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  7 in total

1.  Evaluation of the Antimicrobial and Antibiofilm Effect of Chitosan Nanoparticles as Carrier for Supernatant of Mesenchymal Stem Cells on Multidrug-Resistant Vibrio cholerae.

Authors:  Masoumeh Saberpour; Bita Bakhshi; Shahin Najar-Peerayeh
Journal:  Infect Drug Resist       Date:  2020-07-10       Impact factor: 4.003

Review 2.  Mucosal vaccine delivery: A focus on the breakthrough of specific barriers.

Authors:  Mengwen Huang; Miaomiao Zhang; Hongbin Zhu; Xiaojiao Du; Jun Wang
Journal:  Acta Pharm Sin B       Date:  2022-07-06       Impact factor: 14.903

Review 3.  Demystifying particle-based oral vaccines.

Authors:  Pedro Gonzalez-Cruz; Harvinder Singh Gill
Journal:  Expert Opin Drug Deliv       Date:  2021-07-06       Impact factor: 8.129

Review 4.  Immunomodulation as a Novel Strategy for Prevention and Treatment of Bordetella spp. Infections.

Authors:  Monica C Gestal; Hannah M Johnson; Eric T Harvill
Journal:  Front Immunol       Date:  2019-12-13       Impact factor: 7.561

5.  Preparation of Chitosan Nanoparticles as a Capable Carrier for Antigen Delivery and Antibody Production.

Authors:  Seyyed Aliakbar Mirtajaddini; Mohsen Fathi Najafi; Seyed Ali Vaziri Yazdi; Reza Kazemi Oskuee
Journal:  Iran J Biotechnol       Date:  2021-10-01       Impact factor: 1.671

Review 6.  Immunogenicity of trimeric autotransporter adhesins and their potential as vaccine targets.

Authors:  Arno Thibau; Alexander A Dichter; Diana J Vaca; Dirk Linke; Adrian Goldman; Volkhard A J Kempf
Journal:  Med Microbiol Immunol       Date:  2019-12-01       Impact factor: 3.402

7.  Plant-derived protein bodies as delivery vehicles for recombinant proteins into mammalian cells.

Authors:  Jennifer Schwestka; Marc Tschofen; Stefan Vogt; Sylvain Marcel; Johannes Grillari; Marianne Raith; Ines Swoboda; Eva Stoger
Journal:  Biotechnol Bioeng       Date:  2020-01-30       Impact factor: 4.395

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.